Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Liabilities and Shareholders Equity: 2013-2024

Historic Liabilities and Shareholders Equity for Ocular Therapeutix (OCUL) over the last 12 years, with Dec 2024 value amounting to $457.9 million.

  • Ocular Therapeutix's Liabilities and Shareholders Equity fell 16.21% to $410.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 4.03%. This contributed to the annual value of $457.9 million for FY2024, which is 81.68% up from last year.
  • Per Ocular Therapeutix's latest filing, its Liabilities and Shareholders Equity stood at $457.9 million for FY2024, which was up 81.68% from $252.1 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Liabilities and Shareholders Equity ranged from a high of $457.9 million in FY2024 and a low of $149.3 million during FY2022.
  • In the last 3 years, Ocular Therapeutix's Liabilities and Shareholders Equity had a median value of $252.1 million in 2023 and averaged $286.4 million.
  • Per our database at Business Quant, Ocular Therapeutix's Liabilities and Shareholders Equity spiked by 232.57% in 2020 and then fell by 27.14% in 2022.
  • Over the past 5 years, Ocular Therapeutix's Liabilities and Shareholders Equity (Yearly) stood at $261.9 million in 2020, then declined by 21.76% to $204.9 million in 2021, then decreased by 27.14% to $149.3 million in 2022, then soared by 68.84% to $252.1 million in 2023, then surged by 81.68% to $457.9 million in 2024.